TY - JOUR
T1 - Dry powder inhalers in COPD, lung inflammation and pulmonary infections
AU - Muralidharan, Priya
AU - Hayes, Don
AU - Mansour, Heidi M.
N1 - Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Introduction: The number of pulmonary diseases that are effectively treated by aerosolized medicine continues to grow.Areas covered: These diseases include chronic obstructive pulmonary disease (COPD), lung inflammatory diseases (e.g., asthma) and pulmonary infections. Dry powder inhalers (DPIs) exhibit many unique advantages that have contributed to the incredible growth in the number of DPI pharmaceutical products. To improve the performance, there are a relatively large number of DPI devices available for different inhalable powder formulations. The relationship between formulation and inhaler device features on performance of the drug-device combination product is critical. Aerosol medicine products are drug-device combination products. Device design and compatibility with the formulation are key drug-device combination product aspects in delivering drugs to the lungs as inhaled powders. In addition to discussing pulmonary diseases, this review discusses DPI devices, respirable powder formulation and their interactions in the context of currently marketed DPI products used in the treatment of COPD, asthma and pulmonary infections.Expert opinion: There is a growing line of product options available for patients in choosing inhalers for treatment of respiratory diseases. Looking ahead, combining nanotechnology with optimized DPI formulation and enhancing device design presents a promising future for DPI development.
AB - Introduction: The number of pulmonary diseases that are effectively treated by aerosolized medicine continues to grow.Areas covered: These diseases include chronic obstructive pulmonary disease (COPD), lung inflammatory diseases (e.g., asthma) and pulmonary infections. Dry powder inhalers (DPIs) exhibit many unique advantages that have contributed to the incredible growth in the number of DPI pharmaceutical products. To improve the performance, there are a relatively large number of DPI devices available for different inhalable powder formulations. The relationship between formulation and inhaler device features on performance of the drug-device combination product is critical. Aerosol medicine products are drug-device combination products. Device design and compatibility with the formulation are key drug-device combination product aspects in delivering drugs to the lungs as inhaled powders. In addition to discussing pulmonary diseases, this review discusses DPI devices, respirable powder formulation and their interactions in the context of currently marketed DPI products used in the treatment of COPD, asthma and pulmonary infections.Expert opinion: There is a growing line of product options available for patients in choosing inhalers for treatment of respiratory diseases. Looking ahead, combining nanotechnology with optimized DPI formulation and enhancing device design presents a promising future for DPI development.
KW - Dry powder inhaler devices
KW - Dry powder inhaler products
KW - Inhalable powders
KW - Pulmonary drug delivery
KW - Solid-state formulation
UR - http://www.scopus.com/inward/record.url?scp=84929737310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929737310&partnerID=8YFLogxK
U2 - 10.1517/17425247.2015.977783
DO - 10.1517/17425247.2015.977783
M3 - Review article
C2 - 25388926
AN - SCOPUS:84929737310
SN - 1742-5247
VL - 12
SP - 947
EP - 962
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 6
ER -